A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
European Journal of Cancer2022Vol. 169, pp. 93–102
Citations Over TimeTop 1% of 2022 papers
Richard D. Kim, Bence Kővári, María Carmen Riesco Martínez, Hao Xie, İbrahim Halil Şahin, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Masoumeh Ghayouri, Youngchul Kim, Dae Won Kim
Related Papers
- → Regorafenib: A Review in Metastatic Colorectal Cancer(2018)88 cited
- → Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?(2016)12 cited
- → Regorafenib Improves OS in Asian Patients with mCRC after Previous Failure with Standard Therapy(2014)
- → Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102(2017)
- → Sequenced treatment after regorafenib and survival in metastatic colorectal cancer: a qualitative clinical review(2022)